L. Roy Papp & Associates LLP cut its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 58.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,874 shares of the medical instruments supplier's stock after selling 16,736 shares during the quarter. L. Roy Papp & Associates LLP's holdings in Becton, Dickinson and Company were worth $2,045,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Northcape Wealth Management LLC increased its holdings in Becton, Dickinson and Company by 0.5% during the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock worth $2,248,000 after purchasing an additional 51 shares during the period. Alpha Omega Wealth Management LLC boosted its position in shares of Becton, Dickinson and Company by 5.7% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock worth $225,000 after acquiring an additional 53 shares in the last quarter. Brady Family Wealth LLC boosted its position in shares of Becton, Dickinson and Company by 1.2% during the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock worth $989,000 after acquiring an additional 53 shares in the last quarter. Diversified Trust Co boosted its position in shares of Becton, Dickinson and Company by 4.7% during the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock worth $272,000 after acquiring an additional 53 shares in the last quarter. Finally, Horizon Bancorp Inc. IN boosted its position in shares of Becton, Dickinson and Company by 10.9% during the 1st quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier's stock worth $130,000 after acquiring an additional 56 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.
Becton, Dickinson and Company Stock Down 2.5%
Shares of NYSE BDX opened at $189.06 on Friday. The stock has a market cap of $54.19 billion, a PE ratio of 34.00, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The business has a 50-day moving average price of $189.87 and a 200 day moving average price of $186.61.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The firm had revenue of $5.51 billion during the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business's revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were paid a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is currently 74.82%.
Wall Street Analyst Weigh In
BDX has been the subject of several analyst reports. Argus upped their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Piper Sandler reaffirmed a "neutral" rating and set a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Royal Bank Of Canada initiated coverage on Becton, Dickinson and Company in a research report on Thursday, September 25th. They set a "sector perform" rating and a $211.00 price objective for the company. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research report on Wednesday. Finally, Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $205.40.
Read Our Latest Analysis on BDX
Insider Activity at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the company's stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company's stock, valued at $4,167,375. This represents a 3.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,023 shares of company stock valued at $562,036. 0.36% of the stock is owned by company insiders.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
